Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9416132
APP PUB NO 20140329807A1
SERIAL NO

14234109

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • TOLERO PHARMACEUTICALS, INC.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Brenning, Benjamin Gary Zapopan, MX 5 17
Ho, Koc-Kan Holladay, US 67 1723
Kultgen, Steven G Salt Lake City, US 19 48
Liu, Xiaohui Holladay, US 87 218
Saunders, Michael Sandy, US 52 1217
Xu, Yong Midvale, US 250 1527

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Feb 16, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00